Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

Question 2

How does SIBP-02 compare to the standard Rituximab treatment I might receive?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

Question 4

How often would I need to come in for treatment and monitoring if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the trial in terms of tests and procedures?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks involved in participating in this trial that I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Comparing SIBP-02 and Rituximab Combination With CHOP in Previously Untreated Subjects With CD20+ DLBCL clinical trial (NCT04361279). Contact the study team or your healthcare provider for specific answers.

What this study is about